The Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale

American Heart Journal

Volumn 156, Issue 1, 2008, Pages 44-56

  Mehran, Roxana ^a   Brodie, Bruce ^a   Cox, David A ^a   Grines, Cindy L ^a   Rutherford, Barry ^a   Bhatt, Deepak L ^a   Dangas, George ^a   Feit, Fred ^a   Ohman, E Magnus ^a   Parise, Helen ^a   Fahy, Martin ^a   Lansky, Alexandra J ^a   Stone, Gregg W ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PACLITAXEL; POLYMER; TICLOPIDINE;

ACUTE HEART INFARCTION; ANGIOPLASTY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEMATOLOGIC DISEASE; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; METHODOLOGY; MONOTHERAPY; OUTCOME ASSESSMENT; PACLITAXEL ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESTENOSIS; REVASCULARIZATION; STENT; THROMBOSIS;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROBABILITY; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REFERENCE VALUES; RESEARCH DESIGN; RISK ASSESSMENT; STENTS; SURVIVAL RATE; THROMBOSIS; TIME FACTORS;

EID: 45549102882     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.02.008     Document Type: Article

References (46)

1. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
2. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367 (2006) 569-578
3. Brener S.J., Barr L.A., Burchenal J.E., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98 (1998) 734-741
4. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293 (2005) 1759-1765
5. Grines C.L., Cox D.A., Stone G.W., et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 341 (1999) 1949-1956
6. Lee D.P., Herity N.A., Hiatt B.L., et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 107 (2003) 1497-1501
7. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
8. Neumann F.J., Kastrati A., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 35 (2000) 915-921
9. Ross A.M., Coyne K.S., Reiner J.S., et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. J Am Coll Cardiol 34 (1999) 1954-1962
10. Stone G.W., Grines C.L., Cox D.A., et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
11. Tcheng J.E., Kandzari D.E., Grines C.L., et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 108 (2003) 1316-1323
12. van 't Hof A.W., Ernst N., de Boer M.J., et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 25 (2004) 837-846
13. Zeymer U., Zahn R., Schiele R., et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 26 (2005) 1971-1977
14. Harjai K.J., Stone G.W., Grines C.L., et al. Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. Am J Cardiol 99 (2007) 202-207
15. Manoukian S.V., Feit F., Mehran R., et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49 (2007) 1362-1368
16. Moscucci M., Fox K.A., Cannon C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1815-1823
17. Rao S.V., Jollis J.G., Harrington R.A., et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292 (2004) 1555-1562
18. Hirsh J. Heparin. N Engl J Med 324 (1991) 1565-1574
19. Hirsh J., Warkentin T.E., Shaughnessy S.G., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 1 Suppl (2001) 64S-94S
20. Sobel M., Fish W.R., Toma N., et al. Heparin modulates integrin function in human platelets. J Vasc Surg 33 (2001) 587-594
21. Eikelboom J., White H., and Yusuf S. The evolving role of direct thrombin inhibitors in acute coronary syndromes. J Am Coll Cardiol 41 4 Suppl S (2003) 70S-78S
22. Weitz J.I., and Bates E.R. Direct thrombin inhibitors in cardiac disease. Cardiovasc Toxicol 3 (2003) 13-25
23. Fuchs J., and Cannon C.P. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 92 (1995) 727-733
24. Bittl J.A., Chaitman B.R., Feit F., et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142 (2001) 952-959
25. Bittl J.A., Strony J., Brinker J.A., et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 333 (1995) 764-769
26. Gibson C.M., Morrow D.A., Murphy S.A., et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol 47 (2006) 2364-2373
27. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
28. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
29. Stone G.W., Bertrand M.E., Moses J.W., et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 297 (2007) 591-602
30. Stone G.W., White H.D., Ohman E.M., et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369 (2007) 907-919
31. Stone G.W., Ware J.H., Bertrand M.E., et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management. One-year results from the ACUITY trial. JAMA 298 (2007) 2497-2506
32. Lincoff A.M., Kleiman N.S., Kereiakes D.J., et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 292 (2004) 696-703
33. Stella J.F., Stella R.E., Iaffaldano R.A., et al. Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Invasive Cardiol 16 (2004) 451-454
34. Cohen D.J., Taira D.A., Berezin R., et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation 104 (2001) 3039-3045
35. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
36. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
37. Menichelli M., Parma A., Pucci E., et al. Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 49 (2007) 1924-1930
38. Spaulding C., Henry P., Teiger E., et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
39. Valgimigli M., Percoco G., Malagutti P., et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
40. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
41. Pinto D.S., Stone G.W., Ellis S.G., et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 48 (2006) 32-36
42. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
43. De la Torre JM. Safety of CYPHER and TAXUS Stent Implantation in the 14,000 Patient Multicenter Spanish ESTROFA Registry. Paper presented at: TCT, 2006; Washington, DC.
44. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
45. Bavry A.A., and Bhatt D.L. Acute myocardial infarction and drug-eluting stents: a green light for their use or time for measured restraint?. Am Heart J 153 (2007) 719-721
46. Pasceri V., Patti G., Speciale G., et al. Meta-analysis of clinical trials on use of drug-eluting stents for treatment of acute myocardial infarction. Am Heart J 153 (2007) 749-754